World Journal of Gastrointestinal Oncology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

133

HTML

1188

Figures (1-4)

320

Tables (1-1)

302

Sum=1943

Publishing Process of This Article

Item

Count

Browse

Download

399

Sum=474

Apr 15, 2024 (publication date) through May 27, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef

For:	Zhang XM, Yang T, Xu YY, Li BZ, Shen W, Hu WQ, Yan CW, Zong L. Effectiveness and tolerability of programmed cell death protein-1 inhibitor + chemotherapy compared to chemotherapy for upper gastrointestinal tract cancers. World J Gastrointest Oncol 2024; 16(4): 1613-1625 [PMID: 38660631 DOI: 10.4251/wjgo.v16.i4.1613]
URL:	https://www.wjgnet.com/1948-5204/full/v16/i4/1613.htm

Number	Citing Articles
1	Yunnan Zhang, Wenxing Peng, Wei Yang, Wenzhou Zhang, Yannan Fan. Efficacy and safety of programmed cell death protein-1 inhibitor for first-line therapy of advanced gastric or gastroesophageal junction cancer: a network meta-analysis. Frontiers in Immunology 2025; 16 doi: 10.3389/fimmu.2025.1500954
2	Ahmed Reda Bahr, Ahmed Magdy Hassan, Mohamed Wagdy, Mahmoud Abdelkader, Ahmed Samy Elgammal. Efficacy and Safety of Tislelizumab in Combination with Chemotherapy versus Placebo Plus Chemotherapy in Patients with Advanced Gastric Cancer or Gastroesophageal Junction Cancer: A Systematic Review of Randomized Controlled Trials. ASIDE Gastroenterology 2025; 1(2): 16 doi: 10.71079/ASIDE.GI.06052577